87P ctDNA analysis as a prognostic factor for early-stage and oligometastatic patients treated with radiotherapy

Abstract

High precision radiotherapy techniques, as stereotactic body radiotherapy (SBRT), are increasingly used in the management of non-resectable early-stage lung cancer and also in oligometastatic disease, usually with curative intent. However, there is a need for personalized prognosis biomarkers to stratify patients, adapt treatments and assess their performance. Although, nowadays, more than 50% of cancer patients require radiotherapy, Genomics has not yet been integrated into the clinical practice of radiation oncology.